We are live on ! Find out more
DAM

DLD Asset Management Portfolio holdings

AUM $1.51B Turnover 51.11%
1-Year Est. Return 5.32%
This Fund
S&P 500
This Quarter Est. Return
+0.48%
1 Year Est. Return
+5.32%
3 Year Est. Return
+10.27%
5 Year Est. Return
+32.59%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$362M
Cap. Flow
-$348M
Cap. Flow %
-25.31%
Top 10 Hldgs %
62.01%
Holding
142
New
43
Increased
15
Reduced
9
Closed
60
Avg Time Held Equity + Options
0.2 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.3 years
Avg Time Held Equity only
0.2 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.3 years

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.94%
2 Technology 3.93%
3 Industrials 2.49%
4 Consumer Staples 2.13%
5 Healthcare 0.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
NDRM
126
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-19,000
Closed -$739K –
FNSR
127
DELISTED
Finisar Corp
FNSR
– –
-83,400
Closed -$1.85M –
FNSR
128
PUT
DELISTED
Finisar Corp
FNSR
– –
-21,300
Closed -$472K –
DDC icon
129
DELISTED
Dominion Diamond Corporation
DDC
– –
-25,000
Closed -$355K –

Similar funds

DLD Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, DLD Asset Management held 142 positions worth $1.38B, up 36% from $1.02B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

DLD Asset Management withdrew a net $348M in Q4 2017, closing 60 positions and reducing 9 holdings. Its most notable exit was PTC Therapeutics, an estimated $12.3M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 95% a quarter earlier, followed by Technology and Industrials.

Against the trend, DLD Asset Management opened a new position in Cognizant worth $51.6M.

  • DLD Asset Management's largest Q4 2017 buy was Cognizant: 726,740 shares worth $51.6M.
  • DLD Asset Management added most to Otonomy, Inc. in Q4 2017, an estimated $1.16M increase.
  • DLD Asset Management's biggest Q4 2017 reduction was Lipocine, cutting an estimated $1.03M.
  • DLD Asset Management fully exited PTC Therapeutics in Q4 2017, selling an estimated $12.3M.
  • DLD Asset Management's ten largest holdings make up 62% of its $1.38B portfolio in Q4 2017.
  • DLD Asset Management opened 43 new positions and closed 60 in Q4 2017.
  • DLD Asset Management's portfolio value rose 36% quarter-over-quarter to $1.38B.

Based on DLD Asset Management's 13F filing for Q4 2017, filed 12 Feb 2018.